| Literature DB >> 29117669 |
Seong-Ho Choi1, Jin-Won Chung1, Tark Kim2, Ki-Ho Park3, Mi Suk Lee3, Yee Gyung Kwak4.
Abstract
BACKGROUND/AIMS: Due to advances in diagnostic techniques, clinicians are more frequently performing influenza diagnostic tests and referring to their test results ahead of the administration of neuraminidase inhibitors (NAIs). To investigate the clinical significance of the time from symptom onset to laboratory diagnosis, we reviewed the clinical characteristics of adult patients with influenza who had an early laboratory diagnosis (ED) or a late laboratory diagnosis (LD) at one of four tertiary care centers during a seasonal outbreak of influenza.Entities:
Keywords: Antiviral agents; Diagnosis; Influenza, human
Mesh:
Substances:
Year: 2017 PMID: 29117669 PMCID: PMC5840597 DOI: 10.3904/kjim.2016.226
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Baseline characteristics of adult patients with seasonal influenza who visited one of four tertiary medical centers in South Korea during spring 2014, according to the time from symptom onset to influenza diagnostic testing
| Characteristic | Time from symptom onset to diagnostic testing | |||
|---|---|---|---|---|
| 0–1 Day (ED group) (n = 661) | 2-3 Days (n = 554) | 4–7 Days (LD group) (n = 190) | ||
| Male sex | 245 (37.1) | 233 (42.1) | 71 (37.4) | 0.94 |
| Age, yr | 42.2 ± 18.9 | 42.0 ± 17.6 | 48.1 ± 19.2 | < 0.001 |
| ≥ 50 | 217 (32.8) | 159 (28.7) | 88 (46.3) | 0.001 |
| ≥ 65 | 108 (16.3) | 78 (14.1) | 49 (25.8) | 0.003 |
| Underlying disease or condition | 112 (16.9) | 85 (15.3) | 40 (21.1) | 0.19 |
| Diabetes | 46 (7.0) | 39 (7.0) | 24 (12.6) | 0.01 |
| Cerebrovascular disease | 30 (4.5) | 10 (1.8) | 10 (5.3) | 0.68 |
| Solid tumor | 24 (3.6) | 19 (3.4) | 4 (2.1) | 0.30 |
| Bronchial asthma | 23 (3.5) | 14 (2.5) | 6 (3.2) | 0.83 |
| Chronic renal disease | 17 (2.6) | 5 (0.9) | 4 (2.1) | 1.00 |
| Chronic lung disease | 15 (2.3) | 25 (4.5) | 9 (4.7) | 0.07 |
| Pregnancy | 14 (2.1) | 10 (1.8) | 6 (3.2) | 0.42 |
| Congestive heart failure | 6 (0.9) | 6 (1.1) | 6 (3.2) | 0.03 |
| Hematologic malignancy | 5 (0.8) | 1 (0.2) | 2 (1.1) | 0.66 |
| Dialysis | 4 (0.6) | 3 (0.5) | 1 (0.5) | 1.00 |
| Liver cirrhosis | 4 (0.6) | 0 | 4 (2.1) | 0.08 |
| Type of influenza | < 0.001 | |||
| Influenza A | 515 (77.9) | 391 (70.6) | 111 (58.4) | |
| Influenza B | 144 (21.8) | 163 (29.4) | 77 (40.5) | |
| Co-infection of influenza A and B | 2 (0.3) | 0 | 2 (1.1) | |
| Test(s) used for influenza diagnosis | < 0.001 | |||
| Rapid influenza detection test | 617 (93.3) | 519 (93.7) | 160 (84.2) | |
| PCR test | 26 (3.9) | 20 (3.6) | 21 (11.1) | |
| Both tests | 18 (2.7) | 15 (2.7) | 9 (4.7) | |
Values are presented as number (%) or mean ± SD.
ED, early laboratory diagnosis; LD, late laboratory diagnosis; PCR, polymerase chain reaction.
ED vs. LD.
Clinical features, management, and outcomes of adult patients with seasonal influenza who visited one of four tertiary medical centers in South Korea during spring 2014, according to the time from symptom onset to influenza diagnostic testing
| Characteristic | Time from symptom onset to diagnostic testing | |||
|---|---|---|---|---|
| 0–1 Day (ED group) (n = 661) | 2–3 Days (n = 554) | 4–7 Days (LD group) (n = 190) | ||
| Presenting symptom | ||||
| Cough | 528/660 (80.0) | 484 (87.4) | 166 (87.4) | 0.02 |
| Sputum production | 337/660 (51.1) | 339 (61.2) | 121 (63.7) | 0.002 |
| Rhinorrhea | 312/660 (47.3) | 248 (44.8) | 92 (48.4) | 0.78 |
| Sore throat | 347/660 (52.6) | 293 (52.9) | 96 (50.5) | 0.62 |
| Dyspnea | 37/660 (5.6) | 39 (7.0) | 28 (14.7) | < 0.001 |
| Fever | 601/660 (91.1) | 499 (90.1) | 155 (81.6) | < 0.001 |
| Myalgia | 419/660 (63.5) | 325 (58.7) | 98 (51.6) | 0.003 |
| Clinical severity | ||||
| Hospitalization | 126 (19.1) | 114 (20.6) | 55 (28.9) | 0.003 |
| Admission to intensive care unit | 6 (0.9) | 10 (1.8) | 7 (3.7) | 0.01 |
| Pneumonia | 28 (4.2) | 28 (5.1) | 31 (16.3) | < 0.001 |
| Treatment | ||||
| Oxygen supplementation | 29/660 (4.4) | 25 (4.5) | 15 (7.9) | 0.06 |
| Use of neuraminidase inhibitor | 595 (90.0) | 495 (89.4) | 156 (82.1) | 0.003 |
| Within 2-day after the onset of symptoms | 589/595 (99.0) | 279/495 (56.4) | 4/156 (2.6) | < 0.001 |
| Within 2-day after diagnostic testing | 590/595 (99.2) | 493/495 (99.6) | 152/156 (97.4) | 0.10 |
| Antibiotic therapy | 119 (18.0) | 104 (18.8) | 48 (25.3) | 0.03 |
| Outcomes of hospitalized patients | 0.95 | |||
| Survived | 118/126 (93.7) | 106/113 (93.8) | 48/52 (92.3) | |
| Died in hospital | 4/126 (3.2) | 3/113 (2.7) | 2/52 (3.8) | |
| Transferred to another hospital | 4/126 (3.2) | 4/113 (3.5) | 2/52 (3.8) | |
Values are presented as number (%).
ED, early laboratory diagnosis; LD, late laboratory diagnosis.
ED vs. LD.